Cleary Gottlieb Steen & Hamilton and Goodwin Procter are advising on Tokyo-based Takeda Pharmaceutical’s $6 billion acquisition of Nimbus Lakshmi, a wholly-owned subsidiary of U.S.-based clinical-stage, structure-based drug discovery company Nimbus Therapeutics.
This marks the sixth overseas acquisition by Takeda since February 2021, when it acquired an exclusive worldwide license to the Engenious vector technology platform from U.S.-based clinical-stage biopharmaceutical company Ensoma Inc for $1.35 billion, according to financial data analytics platform operator Dealogic.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
